Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | APAF1 | O14727 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | ADK | P55263 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30100700 | 1.00 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2ACASP3APAF1 | |
| SCHEMBL5668583 | 0.87 | MEN1 (0.55) | L3MBTL1MEN1KMT2ACASP3APAF1 | |
| SCHEMBL30489292 | 0.86 | POLB (0.55) | MEN1KMT2AGAADRD2DRD4 | |
| SCHEMBL28995159 | 0.86 | POLB (0.55) | MEN1KMT2AGAADRD2DRD4 | |
| SCHEMBL31370950 | 0.86 | L3MBTL1 (0.56) | L3MBTL1MEN1KMT2ACASP3APAF1 | |
| SCHEMBL28844252 | 0.86 | L3MBTL1 (0.53) | L3MBTL1MEN1KMT2ACASP3APAF1 | |
| SCHEMBL30489293 | 0.85 | MEN1 (0.48) | L3MBTL1MEN1KMT2ADRD2GSK3B | |
| SCHEMBL28995167 | 0.85 | MEN1 (0.48) | L3MBTL1MEN1KMT2ADRD2GSK3B | |
| SCHEMBL31414463 | 0.83 | XIAP (0.51) | MEN1KMT2ACASP3APAF1GAA | |
| SCHEMBL26604864 | 0.83 | XIAP (0.51) | MEN1KMT2ACASP3APAF1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| WO-2021151062-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERISTY (US) | 2021-07-29 | — | — | WO | disclosed |
| EP-1622874-B1 | 3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070105845-A1 | Quinolone derivatives | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105845-A1 | Quinolone derivatives | NQO2, NQO1, RECQL | L3MBTL1 4674/4885MEN1 694/4885KMT2A 2950/4885 |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | L3MBTL1 2442/4885MEN1 2755/4885KMT2A 647/4885 |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | L3MBTL1 186/4885MEN1 4612/4885KMT2A 565/4885 |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | L3MBTL1 3451/4885MEN1 2243/4885KMT2A 2954/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | L3MBTL1 3499/4885MEN1 237/4885KMT2A 2399/4885 |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PAH, ALDH2, IDH2 | L3MBTL1 4720/4885MEN1 1551/4885KMT2A 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.